share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q：2024財年一季報
美股SEC公告 ·  2024/05/15 08:35

Moomoo AI 已提取核心訊息

ZyVersa Therapeutics, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced a net loss of $2.8 million, a decrease from the $3.5 million net loss in the same period the previous year. Research and development expenses decreased by 51.4% to $513,000, primarily due to lower manufacturing costs for IC100 and reduced payroll costs. General and administrative expenses also saw a reduction of 34.6% to $2.3 million, attributed to decreased payments related to the PIPE shares, lower bonus accruals, and reduced accounting fees. The company's cash position at the end of the quarter was $2.0 million. ZyVersa is focused on developing drugs for renal or inflammatory diseases and has not yet generated revenue from product sales. The company's future plans include continuing the clinical development of its lead drug candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations.
ZyVersa Therapeutics, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced a net loss of $2.8 million, a decrease from the $3.5 million net loss in the same period the previous year. Research and development expenses decreased by 51.4% to $513,000, primarily due to lower manufacturing costs for IC100 and reduced payroll costs. General and administrative expenses also saw a reduction of 34.6% to $2.3 million, attributed to decreased payments related to the PIPE shares, lower bonus accruals, and reduced accounting fees. The company's cash position at the end of the quarter was $2.0 million. ZyVersa is focused on developing drugs for renal or inflammatory diseases and has not yet generated revenue from product sales. The company's future plans include continuing the clinical development of its lead drug candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations.
絲維薩治療公司是一家處於臨床階段的生物製藥公司，報告了2024年3月31日結束的季度的財務業績。公司淨虧損280萬美元，與去年同期的350萬美元淨虧損相比有所下降。研發費用下降了51.4%至513,000美元，主要由於IC100製造成本降低以及減少人員薪資支出。總務及管理費用也下降了34.6%至230萬美元，這歸因於與PIPE股份相關的支付額度降低，獎金計提也降低，以及減少會計費用。該公司季度末的現金頭寸爲200萬美元。絲維薩專注於開發腎臟或炎症性疾病藥物，尚未從產品銷售中獲得營業收入。公司的未來計劃包括繼續開發其領先的候選藥物VAR 200和IC 100，以及尋求進一步的資金支持持續運營。
絲維薩治療公司是一家處於臨床階段的生物製藥公司，報告了2024年3月31日結束的季度的財務業績。公司淨虧損280萬美元，與去年同期的350萬美元淨虧損相比有所下降。研發費用下降了51.4%至513,000美元，主要由於IC100製造成本降低以及減少人員薪資支出。總務及管理費用也下降了34.6%至230萬美元，這歸因於與PIPE股份相關的支付額度降低，獎金計提也降低，以及減少會計費用。該公司季度末的現金頭寸爲200萬美元。絲維薩專注於開發腎臟或炎症性疾病藥物，尚未從產品銷售中獲得營業收入。公司的未來計劃包括繼續開發其領先的候選藥物VAR 200和IC 100，以及尋求進一步的資金支持持續運營。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間